NFKB1 and cystic fibrosis: Our data show that sotagliflozin treatment reduced the levels of NF-κB, significantly ameliorated lobular and portal inflammation, and attenuated the expression of cytokines, included TNF-α and IL-6 in CF rabbit liver tissues.